Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VRCA 
Verrica Pharmaceuticals Inc (VRCA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VRCA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -39.17% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.59M USD | Price to earnings Ratio - | 1Y Target Price 3.33 |
Price to earnings Ratio - | 1Y Target Price 3.33 | ||
Volume (30-day avg) 473466 | Beta 1.45 | 52 Weeks Range 0.39 - 11.41 | Updated Date 03/31/2025 |
52 Weeks Range 0.39 - 11.41 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3292.73% |
Management Effectiveness
Return on Assets (TTM) -59.89% | Return on Equity (TTM) -1546.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 38212665 | Price to Sales(TTM) 5.1 |
Enterprise Value 38212665 | Price to Sales(TTM) 5.1 | ||
Enterprise Value to Revenue 5.05 | Enterprise Value to EBITDA -11.7 | Shares Outstanding 91780000 | Shares Floating 34185294 |
Shares Outstanding 91780000 | Shares Floating 34185294 | ||
Percent Insiders 43.3 | Percent Institutions 32.65 |
Analyst Ratings
Rating 3.67 | Target Price 3.33 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Verrica Pharmaceuticals Inc
Company Overview
History and Background
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company founded in 2013. It focuses on developing and commercializing novel treatments for skin diseases with significant unmet needs. A key milestone was the FDA approval of Ycanth.
Core Business Areas
- Dermatology Therapeutics: Focuses on developing and commercializing treatments for viral skin diseases and other dermatological conditions.
Leadership and Structure
The company is led by a management team with experience in dermatology and pharmaceuticals. The organizational structure consists of executive leadership, research and development, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Ycanth (cantharidin): Ycanth is a topical solution approved for the treatment of molluscum contagiosum. Revenue figures vary but are growing slowly. Key competitors include compounding pharmacies, and off-label uses of other treatments for molluscum, and other pharmaceutical companies exploring this space.
Market Dynamics
Industry Overview
The dermatology therapeutics market is characterized by increasing demand for treatments for various skin conditions, including viral diseases, acne, psoriasis, and skin cancer. The market is driven by an aging population, rising awareness of skin health, and the development of innovative therapies.
Positioning
Verrica Pharmaceuticals is positioned as a specialty dermatology company focused on addressing unmet needs in viral skin diseases like molluscum contagiosum. Their competitive advantage lies in their FDA-approved product, Ycanth, and their focus on this niche area.
Total Addressable Market (TAM)
The total addressable market for molluscum contagiosum treatments is estimated to be in the hundreds of millions of dollars. Verrica is positioned to capture a significant portion of this TAM with Ycanth, however, slow revenue growth and competition have hampered growth.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Ycanth)
- Focus on a specific therapeutic area (viral skin diseases)
- Experienced management team
- Proprietary formulation technology
Weaknesses
- Limited product portfolio
- Dependence on a single product for revenue
- Small market capitalization
- History of losses
Opportunities
- Expansion into new indications (e.g., wart treatment)
- Strategic partnerships
- Acquisition of complementary assets
- Geographic expansion
Threats
- Competition from generic products or alternative therapies
- Regulatory challenges
- Reimbursement issues
- Clinical trial failures
Competitors and Market Share
Key Competitors
- DERM
- GRTS
- AVEO
Competitive Landscape
Verrica faces competition from larger dermatology companies with established sales and marketing infrastructure. Verrica's advantage lies in its focus on specific niche areas and its FDA-approved product. However, Verrica needs to improve market awareness and compete more effectively with established players.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow due to regulatory delays and slower than anticipated market uptake of their products.
Future Projections: Analyst estimates project slow growth, contingent on successful commercialization of current products and regulatory approval for pipeline candidates.
Recent Initiatives: Recent initiatives include expanding the sales force, and pursuing label expansion for Ycanth, and acquiring a device to treat warts.
Summary
Verrica Pharmaceuticals is a specialty dermatology company with one FDA-approved product, Ycanth, for the treatment of molluscum contagiosum. While Ycanth provides a revenue stream, the company is reliant on this single product and has struggled with consistent growth. The company's prospects hinge on expanding Ycanth's indications, successfully commercializing its pipeline candidates and improving its market position against larger competitors. Raising capital may be difficult in the future as the company has historically lost money.
Similar Companies
DERM
Journey Medical Corp
DERM
Journey Medical Corp
GRTS
Gritstone Oncology Inc
GRTS
Gritstone Oncology Inc
Sources and Disclaimers
Data Sources:
- Verrica Pharmaceuticals Inc. SEC Filings (10-K, 10-Q, 8-K)
- Company Press Releases
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verrica Pharmaceuticals Inc
Exchange NASDAQ | Headquaters West Chester, PA, United States | ||
IPO Launch date 2018-06-15 | President, CEO & Director Dr. Jayson M. Rieger M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 71 | Website https://www.verrica.com |
Full time employees 71 | Website https://www.verrica.com | ||
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, engages in the development and sales of medications for the treatment of skin diseases in the United States. The company's product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.